2004
Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction
Costantini CO, Stone GW, Mehran R, Aymong E, Grines CL, Cox DA, Stuckey T, Turco M, Gersh BJ, Tcheng JE, Garcia E, Griffin JJ, Guagliumi G, Leon MB, Lansky AJ. Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction. Journal Of The American College Of Cardiology 2004, 44: 305-312. PMID: 15261923, DOI: 10.1016/j.jacc.2004.03.058.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionIIb/IIIa inhibitorsTissue-level perfusionMyocardial perfusionPrimary angioplastyMyocardial infarctionGlycoprotein IIb/IIIa inhibitionGlycoprotein IIb/IIIa inhibitorsGP IIb/IIIa inhibitorsClinical implicationsIIb/IIIa inhibitionSimilar long-term mortalityLarge-scale prospective studiesMechanical reperfusion strategiesLong-term mortalityMyocardial blush gradeMinority of patientsNormal myocardial perfusionDistinct risk categoriesBlush gradePrimary PCIReperfusion strategyMyocardial reperfusionBalloon angioplastyPrognostic importanceImportance of mitral regurgitation inpatients undergoing percutaneous coronaryintervention for acute myocardial infarction The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial
Pellizzon GG, Grines CL, Cox DA, Stuckey T, Tcheng JE, Garcia E, Guagliumi G, Turco M, Lansky AJ, Griffin JJ, Cohen DJ, Aymong E, Mehran R, O'Neill WW, Stone GW. Importance of mitral regurgitation inpatients undergoing percutaneous coronaryintervention for acute myocardial infarction The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. Journal Of The American College Of Cardiology 2004, 43: 1368-1374. PMID: 15093869, DOI: 10.1016/j.jacc.2003.11.046.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalFemaleHumansImmunoglobulin Fab FragmentsMaleMiddle AgedMitral Valve InsufficiencyMyocardial InfarctionPlatelet Aggregation InhibitorsPrognosisProspective StudiesSeverity of Illness IndexStentsSurvival AnalysisTreatment OutcomeConceptsAcute myocardial infarctionLeft ventricular ejection fractionMechanical reperfusion therapySevere mitral regurgitationMitral regurgitationIndex procedureReperfusion therapyIndependent predictorsMyocardial infarctionLate Angioplasty Complications (CADILLAC) trialPresence of MRHigher Killip classMechanical reperfusion strategiesNon-shock patientsHigh-risk patientsLong-term mortalityTriple vessel diseasePercutaneous coronary interventionVentricular ejection fractionMild mitral regurgitationControlled AbciximabKillip classReperfusion strategyComplications TrialCoronary intervention
2003
Baseline features and clinical results in patients excluded from randomization from a large international trial of reperfusion strategies in acute myocardial infarction: The CADILLAC Registry
Turco M, Cox D, Garcia E, Tcheng J, Griffin J, Guagliumi G, Stuckey T, Carroll J, Grines C, Rutherford B, Slack S, Fahy M, Mehran R, Lansky A, Stone G. Baseline features and clinical results in patients excluded from randomization from a large international trial of reperfusion strategies in acute myocardial infarction: The CADILLAC Registry. Journal Of The American College Of Cardiology 2003, 41: 368. DOI: 10.1016/s0735-1097(03)82163-0.Peer-Reviewed Original Research
2002
Comparison of Angioplasty with Stenting, with or without Abciximab, in Acute Myocardial Infarction
Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Lansky AJ. Comparison of Angioplasty with Stenting, with or without Abciximab, in Acute Myocardial Infarction. New England Journal Of Medicine 2002, 346: 957-966. PMID: 11919304, DOI: 10.1056/nejmoa013404.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryAntibodies, MonoclonalCombined Modality TherapyCoronary AngiographyFemaleHumansImmunoglobulin Fab FragmentsMaleMiddle AgedMyocardial InfarctionMyocardial ReperfusionPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexProspective StudiesRecurrenceStentsStrokeConceptsPrimary percutaneous transluminal coronary angioplastyAcute myocardial infarctionPercent of patientsPrimary end pointInfarct-related arteryRate of deathMyocardial infarctionAbciximab therapyReperfusion strategyPlatelet glycoprotein IIb/IIIa inhibitorsGlycoprotein IIb/IIIa inhibitorsTarget vesselIIb/IIIa inhibitorsPercutaneous transluminal coronary angioplastyEnd pointComposite of deathTarget vessel revascularizationIschemia-driven revascularizationTransluminal coronary angioplastyComparison of AngioplastyAbciximab useRecurrent ischemiaExperienced centersCoronary angioplastyCoronary stenting